SCHEMBL15577665

SCHEMBL15577665

CC(C)(C)C(=O)Nc1cncc(F)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.50
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
AR P10275 1/20 0.43
GAA P10253 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
HCAR2 Q8TDS4 1/20 0.42
MAPT P10636 3/20 0.41
GSK3B P49841 1/20 0.41
ALDH1A1 P00352 2/20 0.41
SYK P43405 1/20 0.41
LMNA P02545 1/20 0.41
ALOX12 P18054 1/20 0.41
CLK2 P49760 2/20 0.40
CLK3 P49761 2/20 0.40
DYRK1A Q13627 2/20 0.40
KDM4E B2RXH2 1/20 0.40
TSHR P16473 1/20 0.40
ABL1 P00519 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25145090 0.88 AR (0.45) ARHCAR2DYRK1AABL1
SCHEMBL18247763 0.84 L3MBTL1 (0.44) L3MBTL1NPC1RAB9ASMN1; SMN2AR
SCHEMBL18481112 0.81 L3MBTL1 (0.52) L3MBTL1NPC1RAB9ASMN1; SMN2GAA
SCHEMBL12827167 0.80 DYRK1A (0.50) L3MBTL1NPC1RAB9ASMN1; SMN2HCAR2
SCHEMBL28197800 0.80 AR (0.56) L3MBTL1NPC1RAB9ASMN1; SMN2AR
SCHEMBL12666584 0.80 L3MBTL1 (0.59) L3MBTL1GAANPSR1MAPTALDH1A1
SCHEMBL12266463 0.79 L3MBTL1 (0.50) L3MBTL1NPC1RAB9ASMN1; SMN2AR
SCHEMBL12011570 0.79 L3MBTL1 (0.50) L3MBTL1NPC1RAB9ASMN1; SMN2GAA
SCHEMBL31401067 0.79 L3MBTL1 (0.50) L3MBTL1NPC1RAB9ASMN1; SMN2GAA
SCHEMBL14395618 0.79 NAMPT (0.48) ARHCAR2SYKCA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250250293-A1 INHIBITORS OF MEK KINASE MOSAICA MEDICINES, INC. 2025-08-07 US disclosed
EP-4486750-A1 INHIBITORS OF MEK KINASE Kinnate Biopharma Inc. (US) 2025-01-08 EP disclosed
CN-119137130-A Inhibitors of MEK kinase 金耐特生物制药公司 2024-12-13 CN disclosed
US-12122800-B2 Inhibitors of MEK kinase KINNATE BIOPHARMA INC. (US) 2024-10-22 US disclosed
US-20230416286-A1 INHIBITORS OF MEK KINASE MOSAICA MEDICINES, INC. 2023-12-28 US disclosed
US-11780862-B2 Inhibitors of MEK kinase KINNATE BIOPHARMA INC. (US) 2023-10-10 US disclosed
US-11780862-B2 Inhibitors of MEK kinase KINNATE BIOPHARMA INC. (US) 2023-10-10 US disclosed
US-11780862-B2 Inhibitors of MEK kinase KINNATE BIOPHARMA INC. (US) 2023-10-10 US disclosed
US-20230279033-A1 INHIBITORS OF MEK KINASE MOSAICA MEDICINES, INC. 2023-09-07 US disclosed
WO-2023168203-A1 INHIBITORS OF MEK KINASE KINNATE BIOPHARMA INC. (US) 2023-09-07 WO disclosed
WO-2023168203-A1 INHIBITORS OF MEK KINASE KINNATE BIOPHARMA INC. (US) 2023-09-07 WO disclosed
EP-2895482-B1 HIV PROTEASE INHIBITORS MERCK SHARP & DOHME (US) 2016-10-19 EP disclosed
US-9315475-B2 HIV protease inhibitors MERCK SHARP & DOHME CORP. (US) 2016-04-19 US disclosed
US-9315475-B2 HIV protease inhibitors MERCK SHARP & DOHME CORP. (US) 2016-04-19 US disclosed
US-9315475-B2 HIV protease inhibitors MERCK SHARP & DOHME CORP. (US) 2016-04-19 US disclosed
EP-2895482-A1 HIV PROTEASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2015-07-22 EP disclosed
US-20140200197-A1 HIV PROTEASE INHIBITORS MERCK SHARP & DOHME LLC 2014-07-17 US disclosed
US-20140200197-A1 HIV PROTEASE INHIBITORS MERCK SHARP & DOHME LLC 2014-07-17 US disclosed
WO-2014043019-A1 HIV PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2014-03-20 WO disclosed
WO-2014043019-A1 HIV PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2014-03-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230279033-A1 INHIBITORS OF MEK KINASE BRAF, NRAS, RAF1 L3MBTL1 1542/4885NPC1 2077/4885RAB9A 1427/4885
US-12122800-B2 Inhibitors of MEK kinase BRAF, NRAS, RAF1 L3MBTL1 1542/4885NPC1 2077/4885RAB9A 1427/4885
US-20140200197-A1 HIV PROTEASE INHIBITORS SERPINB1, PREP, PRSS1 L3MBTL1 3163/4885NPC1 325/4885RAB9A 1510/4885
US-20250250293-A1 INHIBITORS OF MEK KINASE BRAF, NRAS, RAF1 L3MBTL1 1542/4885NPC1 2077/4885RAB9A 1427/4885
US-20230416286-A1 INHIBITORS OF MEK KINASE BRAF, NRAS, RAF1 L3MBTL1 1542/4885NPC1 2077/4885RAB9A 1427/4885
US-11780862-B2 Inhibitors of MEK kinase BRAF, NRAS, RAF1 L3MBTL1 1542/4885NPC1 2077/4885RAB9A 1427/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.